GlassScriptPhysician profile
Brittany A Derra
NPI 1033473632
$3,886.97
in general payments reported to CMS, 2019-2025
26 companies · $966 in 2025
The $966 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2021: $36.06 · 2022: $548 · 2023: $976 · 2024: $1,054 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,995.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $578.83 | 2022-2025 | |
| Lilly USA, LLC | $559.12 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $397.73 | 2022-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.82 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Novo Nordisk INC | $374.21 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $198.34 | 2022-2023 | |
| Exact Sciences Corporation | $184.81 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $152.84 | 2022-2024 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $147.15 | 2021-2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $120.69 | 2019 | |
| Glaxosmithkline, LLC. | $111.48 | 2022-2025 | Arexvy, Shingrix, Boostrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.95 | 2023-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $77.01 | 2025 | Breztri |
| E.R. Squibb & Sons, L.L.C. | $64.58 | 2019 | |
| Dexcom, INC. | $64.50 | 2024 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $57.21 | 2023 | Quviviq |
| Seqirus USA INC | $51.08 | 2024-2025 | Fluad, Flucelvax |
| Astellas Pharma US INC | $47.98 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $46.84 | 2023-2025 | Capvaxive, Gardasil 9, Verquvo |
| Axsome Therapeutics, INC. | $46.67 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $28.64 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.42 | 2022 | |
| Amneal Pharmaceuticals LLC | $23.91 | 2022 | |
| Alvogen INC | $17.78 | 2023 | Teriparatide |
| Actelion Pharmaceuticals US, INC. | $16.86 | 2024 | Opsumit, Uptravi |
| Abiomed | $14.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Derra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.